Rafferty Asset Management LLC Has $4.26 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Rafferty Asset Management LLC lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 40.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,201 shares of the company's stock after selling 18,639 shares during the period. Rafferty Asset Management LLC owned approximately 0.09% of Krystal Biotech worth $4,261,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Covestor Ltd increased its holdings in shares of Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after acquiring an additional 642 shares during the period. Avanza Fonder AB acquired a new stake in shares of Krystal Biotech in the 4th quarter worth about $119,000. KBC Group NV increased its holdings in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after acquiring an additional 297 shares during the period. Blue Trust Inc. increased its holdings in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after acquiring an additional 433 shares during the period. Finally, US Bancorp DE increased its holdings in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after acquiring an additional 82 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective on the stock. Chardan Capital reissued a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Citigroup lowered their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a research note on Friday, May 16th. Finally, Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $211.13.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded down $0.24 during trading hours on Friday, hitting $125.05. 298,645 shares of the company's stock traded hands, compared to its average volume of 308,069. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $219.34. The company's fifty day simple moving average is $161.34 and its two-hundred day simple moving average is $166.92. The company has a market cap of $3.61 billion, a price-to-earnings ratio of 41.82 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. On average, analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).